StemCell Institute Q4 FY2026 earnings call

• Core Domestic Business Position

  • Stem Cell Institute is the dominant commercial private cord blood and umbilical cord storage provider in Japan, with 26 years of uninterrupted error-free storage experience and a 99% share of new domestic storage contracts.
  • Holds cooperative agreements with 1,445 out of ~2,000 total obstetric facilities in Japan as of August 2025, giving the firm an unmatchable network and infrastructure advantage over potential new entrants.
  • Current annual new storage volume is ~9,000 specimens, with a current domestic storage penetration rate of 1.5% of total annual births. The firm targets a medium-term penetration rate of 3% to 4% and an annual new storage volume of 20,000 specimens, which would bring total revenue to ~2.5x current levels.
  • Uses dual marketing channels: 60% of new contracts come from in-person outreach at obstetric facilities (mother class presentations and pamphlet placement), while digital marketing drives more initial inquiries but has lower conversion, with many clients converting after in-person follow-up.
  • Operates two cell processing centers in Tokyo and Yokohama with 2,000 specimens monthly processing capacity, and three cryogenic storage facilities with 200,000 total specimens capacity (current inventory is ~100,000 specimens). Processing and storage follow 365-day/24-hour operations to meet the 48-hour post-birth processing requirement, per international standards.
  • Revenue model: Fixed total contract price for 10+ years of storage with installment payment options. Initial technical fees are recognized as revenue in the first contract year, while future annual storage fees are recorded as deferred revenue on the balance sheet and recognized year-over-year. Target gross margin is at minimum 60% to cover ongoing infrastructure and labor costs.

• Clinical Research and New Service Development

  • Collaborates with domestic academic institutions on clinical research for umbilical cord blood stem cell application: high-profile studies include cerebral palsy treatment at Kochi University (recent published results show symptom improvement after treatment) and autism spectrum disorder treatment at Osaka Metropolitan University (ongoing study).
  • Conducts joint basic research with the University of Tokyo on umbilical cord tissue-derived mesenchymal cell use for cleft lip and palate repair.
  • Offers commercially available Family Supernatant service: patient-specific umbilical cord cell culture supernatant (containing cytokines and exosomes) for family use in health and aesthetic applications, limited to the baby and their family with clear provenance for higher safety than generic third-party supernatant products, offered through partnered clinics.

• Southeast Asia (SEA) Expansion Strategy

  • Established a joint venture with the owner family of Indonesia's Sinar Mas Group, a large local conglomerate with >3 trillion yen in annual revenue, after existing personal business relationships. The JV was formed in July 2025 with capital injected in August 2025, and is currently in the launch preparation phase.
  • Targets Singapore and Jakarta (Indonesia) metropolitan area for initial launch, with a target of 1,200 new annual specimens in Singapore and 1,000 new annual specimens in Jakarta within 3-5 years, for a combined 2,200 new specimens annually. Service pricing in SEA is approximately double the price level in Japan.
  • The top incumbent private cord blood bank in Singapore experienced a major operational incident in 2023 where stored specimens thawed and were lost, leading to industry-wide trust erosion and created a market opportunity for Stem Cell Institute's Japanese quality and brand reputation.

• Adjacent Growth

  • Makes minority investments in companies focused on pregnancy and perinatal care, aligned with the firm's existing obstetric network, including social egg freezing and infant cranial reshaping helmet services, to expand the firm's business footprint beyond cell storage over time.

The transcript does not provide segmented absolute financial results or revenue contribution percentages for individual product segments. The firm operates three core business areas: 1) Umbilical cord blood and umbilical cord storage service, which holds 99% domestic market share in commercial private cord blood banking in Japan; 2) Family supernatant manufacturing service from stored umbilical cord tissue, an available service for existing storage clients; 3) Related investment activity in pregnancy and infant healthcare adjacent businesses. The only financial guidance data provided is an estimated 1 billion yen in planned SEA expansion selling, general and administrative pre-revenue start-up costs for the 2026 March fiscal year.

• For the 2026 March fiscal year, management maintains guidance for a new all-time high in full-year revenue and profit, with a planned 12% top-line growth, after 20-30% annual growth in prior periods. The slower projected growth rate is intentional to ensure stable, incremental expansion rather than rapid overextension that could create operational risk.
  • Domestic core business has underlying potential for 15-20% annual growth, and management expects SEA expansion revenue to add incremental top-line growth starting from the 2027 March fiscal year.
  • 1 billion yen in pre-revenue SEA expansion selling, general and administrative costs are included in the 2026 March fiscal year guidance, with no SEA revenue expected to be recognized this fiscal year.
  • For SEA operations, management expects cash break-even within 1 year of launch and accounting net profit within 2-3 years of launch, assuming stable growth.

• Domestic birth numbers have been steadily declining and are not expected to recover, limiting organic domestic growth to penetration gains rather than market size expansion.
  • SEA expansion requires navigating country-specific regulatory frameworks for cell storage and processing, which adds execution risk and timing uncertainty to the launch timeline.
  • Competitive pressure exists in Singapore from three existing incumbent private cord blood banks, requiring the firm to differentiate on quality and brand to gain market share.
  • Gaining obstetric facility cooperation and network access in SEA markets will take time and investment, similar to the multi-decade network building process in Japan.
  • Growth requires sustained marketing investment to increase public awareness of cord blood storage, which remains low in Japan at 1.5% penetration, creating ongoing sales execution risk.

Q: What is the go-to-market strategy for Singapore and Indonesia, and when does management expect the SEA business to become profitable? / A: Singapore is small with only 11 major obstetric facilities, so marketing focuses on promoting Japanese quality and technical safety to gain market share. For Indonesia, the Sinar Mas Group's existing large retail network (with hundreds of thousands of employees across insurance and other consumer businesses) will be leveraged as agents to drive customer acquisition with minimal in-house marketing effort. Management expects cash break-even within 1 year of launch, and accounting profitability within 2-3 years, given the high service prices in the market.

Q: Why is 2026 fiscal year revenue growth guidance lower than prior periods of 20-30% annual growth? / A: The lower 12% projected growth is intentional, not a reflection of weaker underlying demand. Management prioritizes stable, incremental growth to avoid operational issues that could come from trying to double volume too quickly, and the 1 billion yen in SEA start-up costs also moderate the bottom-line growth guidance this year. Domestic core business still has underlying potential for 15-20% annual growth, and SEA revenue will add incremental growth starting next fiscal year.

Q: Are there any religious or regulatory barriers to entering Southeast Asian markets? / A: Management states there are no meaningful religious barriers; cord blood storage is already widely accepted across Muslim-majority Indonesia, Hindu-majority India, and other SEA markets with diverse religious populations. There are regulatory differences across countries: Singapore requires strict health ministry licensing for cell storage facilities, while other markets have looser regulation, but there are no outright bans on the business that would block entry.

Q: When will SEA operations launch, and what is the current infrastructure progress? / A: The joint venture is already established, and facility lease negotiations are in the final stages. Licensing applications will be filed after facility construction is completed, with processes running in parallel to speed up approval. Management targets launch in the first quarter of the 2027 fiscal year, and all work is currently progressing on schedule.